Skip to content
← Full study record

NCT01343277 · MORE INFO

Limitations, agreements, and source contact

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma · Source last updated 2016-08-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
title
Senior Director
Complete source fields
certain Agreement
other Details
A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
title
Senior Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice